Literature DB >> 8768735

Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.

S D Hess1, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson, G Veliçelebi.   

Abstract

Human cDNAs encoding N-methyl-D-aspartate receptor type (NMDAR)1A, NMDAR2A and NMDAR2B subunits were cloned and receptors encoded by these cDNAs were functionally expressed by injection of the respective mRNAs in Xenopus oocytes. The pharmacological properties of recombinant human N-methyl-D-aspartate (NMDA) receptors were characterized by profiling two agonists and four antagonists at both the NMDA and glycine sites in voltage-clamped oocytes. NMDA, glycine and D-serine were significantly more potent at human NMDAR (hNMDAR)1A/2B receptors than at nNMDAR1A/2A, whereas there was no detectable subtype-dependent difference in the potency of glutamate. Of the NMDA-site antagonists tested, CGP 43487 and 3-(2-carboxypiperazin-4-yl) propyl-1-phosphonate exhibited 5.8- and 3.9-fold greater potency, respectively, at hNMDAR1A/2A receptors than at hNMDAR1A/2B. Of the four glycine-site competitive antagonists tested, L-689,560 displayed 5-fold greater potency at hNMDAR1A/2A, whereas 5,7-dichlorokynurenic acid, HA-966 and CGP 58411 did not discriminate between hNMDAR1A/2A and hNMDAR1A/2B. Receptors resulting from injection of hNMDAR1A, hNMDAR2A and hNMDAR2B transcripts in a 1:1:1 ratio were indistinguishable from hNMDAR1A/2B receptors in terms of their sensitivity to NMDA, glycine, D-serine, CGS 19755 and CGP 40116. Ifenprodil was approximately 350-fold more potent at hNMDAR1A/2B than at hNMDAR1A/2A receptors. Ifenprodil sensitivities of receptors formed in oocytes injected with a constant amount of hNMDAR1A mRNA but varying ratios of hNMDAR2A or hNMDAR2B mRNAs were compared. The receptors expressed at a 10:1 ratio of 2A:2B transcripts displayed an ifenprodil sensitivity that would be predicted for a population in which 51% was represented by hNMDAR(1A)2(2A)3 complexes. Our results underscore the need for subtype-selective compounds acting at novel sites to sufficiently probe the pharmacological differences between NMDA receptor subtypes formed by different subunit combinations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8768735

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Characterization of the binding of two novel glycine site antagonists to cloned NMDA receptors: evidence for two pharmacological classes of antagonists.

Authors:  B Chopra; P L Chazot; F A Stephenson
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Authors:  Daniel T Monaghan; Mark W Irvine; Blaise Mathias Costa; Guangyu Fang; David E Jane
Journal:  Neurochem Int       Date:  2012-01-17       Impact factor: 3.921

Review 3.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

4.  Molecular pharmacology of human NMDA receptors.

Authors:  Maiken Hedegaard; Kasper B Hansen; Karen T Andersen; Hans Bräuner-Osborne; Stephen F Traynelis
Journal:  Neurochem Int       Date:  2011-12-17       Impact factor: 3.921

5.  Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model.

Authors:  Peter Heusler; Amélie Tourette; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-22       Impact factor: 3.000

6.  Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures.

Authors:  N Hiroi; G J Marek; J R Brown; H Ye; F Saudou; V A Vaidya; R S Duman; M E Greenberg; E J Nestler
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

7.  Breast cancer expresses functional NMDA receptors.

Authors:  William G North; Guohong Gao; Vincent A Memoli; Roy H Pang; Launa Lynch
Journal:  Breast Cancer Res Treat       Date:  2009-09-26       Impact factor: 4.872

8.  NMDA Receptors in the Central Nervous System.

Authors:  Kasper B Hansen; Feng Yi; Riley E Perszyk; Frank S Menniti; Stephen F Traynelis
Journal:  Methods Mol Biol       Date:  2017

9.  Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.

Authors:  S McKay; N H Griffiths; P A Butters; E B Thubron; G E Hardingham; D J A Wyllie
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 10.  Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Authors:  Erica S Burnell; Mark Irvine; Guangyu Fang; Kiran Sapkota; David E Jane; Daniel T Monaghan
Journal:  J Med Chem       Date:  2018-03-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.